LIGAND PHARMACEUTICALS INCORPORATED Accounts Receivable
LIGAND PHARMACEUTICALS INCORPORATED (LGNYZ) had Accounts Receivable of $67.01 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2026-08-07
- 2026-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $67.01M.
- 2026-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $53.38M.
- 2025-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $59.60M.
- 2025-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $57.56M.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2026-06-30 | $67.01M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $53.38M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $59.60M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $57.56M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $41.29M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $38.49M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $38.38M 10-K · filed 2026-02-27 |
| 2024-09-30 | $34.32M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $37.48M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $28.43M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $32.92M 10-K · filed 2025-02-28 |
| 2023-09-30 | $36.00M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $27.99M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $29.19M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $30.42M 10-K · filed 2024-02-29 |
| 2022-09-30 | $65.17M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $62.31M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $41.80M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $85.45M 10-K · filed 2023-02-28 |
| 2021-09-30 | $64.34M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $58.16M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $54.44M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $56.85M 10-K · filed 2022-02-28 |
| 2020-09-30 | $32.91M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $41.87M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $39.51M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $30.39M 10-K · filed 2021-02-24 |
| 2018-12-31 | $55.85M 10-K · filed 2020-02-27 |